Src



Src family kinase (SFK) is a family of non-receptor tyrosine kinases including nine members: Src, Yes, Fyn, and Fgr, forming the SrcA subfamily, Lck, Hck, Blk, and Lyn in the SrcB subfamily, and Frk in its own subfamily. In immune cells, Src-family kinases (SFKs) have been implicated as critical regulators of a large number of intracellular signaling pathways. Src-family kinases (SFKs) occupy a proximal position in numerous signaling transduction cascades including those emanating from the T and B cell antigen receptors, Fc receptors, growth factor receptors, cytokine receptors, and integrins. In addition to these positive regulatory roles, Src-family kinases (SFKs) can also function as negative regulators of cellular signaling by phosphorylating immunoreceptor tyrosine-based inhibitory motifs (ITIMs) on inhibitory receptors, resulting in recruitment and activation of inhibitory molecules such as the phosphatases SHP-1 and SH2 containing 5′ inositol phosphatase (SHIP-1).

Src Inhibitors & Modulators

1-Naphthyl PP1
(1-NA-PP 1) Cat. No.: HY-13941

Bioactivity: 1-Naphthyl PP1(1-NA-PP 1) is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectively).

Purity: 98.56%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



1-Naphthyl PP1 hydrochloride
(1-NA-PP 1 hydrochloride) Cat. No.: HY-13941B

Bioactivity: 1-Naphthyl PP1(1-NA-PP1) hydrochloride is a selective inhibitor of src family kinases v-Src and c-Fyn as well as the tyrosine kinase c-Abl (IC50 values are 1.0, 0.6, 0.6, 18 and 22 μM for v-Src, c-Fyn, c-Abl, CDK2 and CAMK II respectivel...

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



1-NM-PP1
(PP1 Analog II) Cat. No.: HY-13942

Bioactivity: 1-NM-PP1, a cell-permeable PP1 analog, is a potent **Src family kinases** inhibitor with **IC_{50}**s of 4.3 nM and 3.2 nM for v-Src-as1 and c-Fyn-as1, respectively [1] [2].

Purity: 98.83%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



7-Hydroxy-4-chromone
(7-Hydroxychromone) Cat. No.: HY-N6596

Bioactivity: 7-Hydroxychromone is a **Src kinase** inhibitor with an **IC_{50}** of <300 μM.

Purity: 99.82%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 50 mg



A 419259
(RK-20449) Cat. No.: HY-15764

Bioactivity: A 419259 is a broad-spectrum pyrrolo-pyrimidine inhibitor, designed to enhance selectivity towards the Src family with **IC_{50}** of 9 nM, <3 nM and <3 nM for **Src**, **Lck** and **Lyn**, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



A 419259 trihydrochloride
(RK 20449 trihydrochloride) Cat. No.: HY-15764A

Bioactivity: A 419259 trihydrochloride is a **Src family kinases** inhibitor with **IC_{50}**s of 9 nM, 3 nM and 3 nM for **Src**, **Lck** and **Lyn**, respectively.

Purity: 98.42%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water, 5 mg, 10 mg, 50 mg



A-770041
Cat. No.: HY-11011

Bioactivity: A-770041 is selective and orally active Src-family Lck inhibitor; A-770041 is a 147 nM inhibitor of Lck (1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.

Purity: 99.53%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



AD80
Cat. No.: HY-101963

Bioactivity: AD80, a multikinase inhibitor, inhibits **RET**, **RAF**, **SRC**and **S6K**, with greatly reduced mTOR activity.

Purity: 99.46%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



AMG-47a
Cat. No.: HY-18303

Bioactivity: AMG-47a is a potent inhibitor of Lck and T cell proliferation; exhibits anti-inflammatory activity (ED50 = 11 mg/kg) in the anti-CD3 induced production of IL-2 in mice.

Purity: 98.71%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



AZM475271
(M475271) Cat. No.: HY-13561

Bioactivity: AZM475271 is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2.

Purity: 99.86%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Bosutinib

(SKI-606)

Cat. No.: HY-10158

Bioactivity: Bosutinib is a dual **Src/Abl** inhibitor with **IC_{50}**s of 1.2 nM and 1 nM, respectively.

Purity: 99.83%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg



CSF1R-IN-2

Cat. No.: HY-111787

Bioactivity: CSF1R-IN-2 (compound 5) is an oral-active inhibitor of **SRC**, **MET** and **c-FMS**, with **IC_{50}** values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Dasatinib

(BMS-354825)

Cat. No.: HY-10181

Bioactivity: Dasatinib (BMS-354825) is a dual **Bcr-Abl** and **Src** family tyrosine kinase inhibitor with **IC_{50}**s of 0.6, 0.8, 79 and 37 nM for Abl, Src, c-Kit and c-Kit ^{D816V}, respectively.

Purity: 99.84%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



Dasatinib hydrochloride

(BMS 354825 hydrochloride)

Cat. No.: HY-10181A

Bioactivity: Dasatinib hydrochloride is a potent and dual **Abl^{WT}/ Src** inhibitor **IC_{50}** of 0.6 nM/0.8 nM respectively; also inhibits **$c\text{-}Kit^{WT}$/ $c\text{-}Kit^{D816V}$** with **IC_{50}** of 79 nM/37 nM.

Purity: 98.84%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



eCF506

Cat. No.: HY-112096

Bioactivity: eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase **Src** with an **IC_{50}** of less than 0.5 nM.

Purity: 98.83%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



ENMD-2076

Cat. No.: HY-10987A

Bioactivity: ENMD-2076 is a multi-targeted kinase inhibitor with **IC_{50}**s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.

Purity: 99.23%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



ENMD-2076 Tartrate

Cat. No.: HY-10987

Bioactivity: ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with **IC_{50}**s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for **Aurora A**, **Flt3**, **KDR/VEGFR2**, **Flt4/VEGFR3**, **FGFR1**, **FGFR2**, **Src**, **PDGFRα**, respectively.

Purity: 98.59%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



KB SRC 4

Cat. No.: HY-108488

Bioactivity: KB SRC 4 is a potent, and highly selective **c-Src** inhibitor, with a **K_i** of 44 nM and a **K_d** of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



KX1-004

Cat. No.: HY-18237

Bioactivity: KX1-004 is a potent small molecule inhibitor of Src-PTK as a potential protective drug for NIHL.

Purity: 99.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Lck Inhibitor

Cat. No.: HY-12072

Bioactivity: Lck Inhibitor is a new class of compounds that are potent inhibitors of Lck with an IC50 value of 7 nM. IC50 Value: 7 nM [1] Target: Lck in vitro: Lck Inhibitor (compound 25) exhibited good potency in the T-cell receptor-induced IL-2 secretion assay (IL- 2) and also inhibited subsequent T-cell...

Purity: 98.85%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Lck inhibitor 2

Cat. No.: HY-10644

Bioactivity: Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively

Purity: 99.73%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



MNS

(NSC 170724; 5-(2-Nitrovinyl)benzodioxole)

Cat. No.: HY-78263

Bioactivity: MNS is a potent and selective inhibitor of Src and Syk tyrosine kinases. target: src, syk. [1] IC50:29.3 (src), 2.5 uM (syk); [1] In vitro: no direct effects on protein kinase C, Ca2+ mobilization, Ca2+-dependent enzymes, PKC activation. MNS potently prevents GPIIb/IIIa activation and platelet...

Purity: 99.23%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 100 mg, 200 mg, 500 mg



PD173955

Cat. No.: HY-10395

Bioactivity: PD173955 is src family-selective tyrosine kinase inhibitor with IC50 of ~22 nM for Src, Yes and Abl kinase; less potent for FGFRα and no activity on InsR and PKC.

Purity: 99.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg



Pelitinib

(EKB-569; WAY-EKB 569)

Cat. No.: HY-32718

Bioactivity: Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of **EGFR** with an **IC_{50}** of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with **IC_{50}**s of 282, 800, and 1255 nM, respectively.

Purity: 98.18%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Ponatinib

(AP24534)

Cat. No.: HY-12047

Bioactivity: Ponatinib is a potent, orally available multi-targeted kinase inhibitor with **IC_{50}**s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for **Abl**, **PDGFRα**, **VEGFR2**, **FGFR1**, and **Src**, respectively.

Purity: 98.96%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



PP1

(AGL 1872; EI 275)

Cat. No.: HY-13804

Bioactivity: PP1 is a potent, and **Src** family-selective tyrosine kinase inhibitor with **IC_{50}** of 5 and 6 nM for Lck and Fyn, respectively.

Purity: 98.39%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



PP121

Cat. No.: HY-10372

Bioactivity: PP121 is a multi-targeted kinase inhibitor with **IC_{50}**s of 10, 60, 12, 14, 2 nM for **mTOR**, **DNK-PK**, **VEGFR2**, **Src**, **PDGFR**, respectively.

Purity: 98.89%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



PP2

(AGL 1879)

Cat. No.: HY-13805

Bioactivity: PP2 is a reversible and ATP-competitive **Src** family kinases inhibitor with **IC_{50}**s of 4 and 5 nM for **Lck** and **Fyn**, respectively.

Purity: 98.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PP58

Cat. No.: HY-18622

Bioactivity: PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits **PDGFR**, **FGFR** and **Src** family activities with nanomolar **IC_{50}** values.

Purity: 98.07%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg



Rebastinib

(DCC-2036)

Cat. No.: HY-13024

Bioactivity: Rebastinib (DCC-2036) is a conformational control **Bcr-Abl** inhibitor for **$Abl1^{WT}$** and **$Abl1^{T315I}$** with **IC_{50}** of 0.8 nM and 4 nM, also inhibits SRC, KDR, FLT3, and Tie-2, and low activity to seen towards c-Kit.

Purity: 99.91%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



RK-24466

(KIN 001-51) Cat. No.: HY-108318

Bioactivity: RK-24466 (KIN 001-51) is a potent and selective **Lck** inhibitor; inhibits Lck (64-509) and LckCD isoforms with **IC_{50}**s of less than 1 and 2 nM, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg



Saracatinib

(AZD0530) Cat. No.: HY-10234

Bioactivity: Saracatinib (AZD0530) is a potent **Src** family inhibitor with **IC_{50}**s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk and shows high selectivity over other tyrosine kinases.

Purity: 99.88%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



Scutellarein

(6-Hydroxyapigenin; 4',5,6,7-Tetrahydroxyflavone) Cat. No.: HY-N0752

Bioactivity: Scutellarin, a main active ingredient extracted from Erigeron breviscapus (Vant.) Hand-Mazz., has been wildly used to treat acute cerebral infarction and paralysis induced by cerebrovascular diseases.

Purity: 99.02%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg



Secretin, canine

Cat. No.: HY-P1784

Bioactivity: Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine can regulates gastric chief cell function and paracellular permeability in canine gastric monolayers by a Src kinase-dependent pathway [1].

Purity: >98%
Clinical Data: No Development Reported
Size:

Src Inhibitor 1

(Src Kinase Inhibitor 1; Src-I1) Cat. No.: HY-101053

Bioactivity: Src Inhibitor 1 is a potent and selective dual site **Src** tyrosine kinase inhibitor with **IC_{50}** values of 44 nM for Src and 88nM for Lck.

Purity: 99.28%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg



SU6656

Cat. No.: HY-B0789

Bioactivity: SU 6656 is a **Src family kinases** inhibitor with **IC_{50}**s of 280, 20, 130, 170 nM for Src, Yes, Lyn, and Fyn, respectively.

Purity: 97.19%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



T338C Src-IN-1

Cat. No.: HY-16905

Bioactivity: T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase).

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



T338C Src-IN-2

Cat. No.: HY-16906

Bioactivity: T338C Src-IN-2 is a potent mutant c-Src T338C kinase inhibitor with IC50 of 317 nM; also inhibits T338C/V323A and T338C/V323S with IC50 of 57 nM/19 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg



TG 100572

Cat. No.: HY-10184

Bioactivity: TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has **IC_{50}**s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



TG 100572 Hydrochloride

Cat. No.: HY-10185

Bioactivity: TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has **IC_{50}**s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

Purity: 98.44%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg



TG 100801

Cat. No.: HY-10186

Bioactivity: TG 100801 is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has **IC_{50}**s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for...
Purity: 98.60%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg



TG 100801 Hydrochloride

Cat. No.: HY-10187

Bioactivity: TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits **receptor tyrosine kinases** and **Src kinases**; has **IC_{50}**s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1,...
Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



Tirbanibulin

(KX2-391; KX-01)

Cat. No.: HY-10340

Bioactivity: Tirbanibulin (KX2-391) is an inhibitor of **Src** that targets the peptide substrate site of Src, with **GI_{50}** of 9-60 nM in cancer cell lines.

Purity: >98%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 50 mg, 100 mg



Tirbanibulin dihydrochloride

(KX2-391 (dihydrochloride); KX-01 (dihydrochloride))

Cat. No.: HY-10340A

Bioactivity: Tirbanibulin (dihydrochloride) (KX2-391 (dihydrochloride)) is an inhibitor of **Src** that targets the peptide substrate site of Src, with **GI_{50}** of 9-60 nM in cancer cell lines.

Purity: 96.24%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Tirbanibulin Mesylate

(KX2-391 (Mesylate); KX01 (Mesylate))

Cat. No.: HY-10340B

Bioactivity: Tirbanibulin (Mesylate) (KX2-391 (Mesylate)) is an inhibitor of **Src** that targets the peptide substrate site of Src, with **GI_{50}** of 9-60 nM in cancer cell lines.

Purity: 99.97%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Tolimidone

(MLR-1023)

Cat. No.: HY-59047

Bioactivity: Tolimidone is a potent and selective allosteric activator of **Lyn kinase** with an **EC_{50}** of 63 nM.

Purity: 99.98%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg



UM-164

(DAS-DFGO-II)

Cat. No.: HY-112182

Bioactivity: UM-164 (DAS-DFGO-II) is a highly potent inhibitor of **c-Src** with a **K_d** of 2.7 nM. UM-164 also potently inhibits **p38α** and **p38β**.

Purity: 99.08%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



WEHI-345 analog

Cat. No.: HY-100112

Bioactivity: WEHI-345 analog is a Src inhibitor, extracted from patent WO/2012003544A1, compound example 71. Target:Src WEHI-345 (analog) is a protein kinase inhibitor. A family of proto-oncogenic TPKs referred to herein as SFKs (Src family kinases) have provided researchers with a better understanding...
Purity: 99.47%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg



WH-4-023

(Dual LCK/SRC inhibitor)

Cat. No.: HY-12299

Bioactivity: WH-4-023 is a potent and selective dual **Lck**/ **Src** inhibitor with **IC_{50}** of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.

Purity: 99.93%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



XL228

Cat. No.: HY-15749

Bioactivity: XL228 is a multi-targeted tyrosine kinase inhibitor with **IC_{50}**s of 5, 3.1, 1.6, 6.1, 2 nM for **Bcr-Abl**, **Aurora A**, **IGF-1R**, **Src** and **Lyn**, respectively.

Purity: 99.61%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg